A clinical trial record update for thymosin beta-4 was logged on October 21, 2026. The trial, registered as NCT02974907 and titled "Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2," is a Phase 3 study. Its current status is listed as completed.
RGN-259 is an ophthalmic solution formulation containing thymosin beta-4 studied for dry eye syndrome. The ARISE-2 designation refers to this specific Phase 3 protocol within the trial's broader development program. This update reflects only the trial's status as recorded in the registry entry.
No results, efficacy outcomes, or safety findings are included in this update. The completed status refers to the trial reaching its defined endpoint for conduct, not to any specific outcome data being released or reviewed. Thymosin beta-4 remains classified as an unapproved compound under research investigation, and RGN-259 has not been evaluated here for approval status.
Readers should note that trial completion indicates the study has concluded per its registered design, but does not by itself confirm any particular result. For more background on this compound, see the linked compound overview.